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Background: Karapxa decoction (KD) is a Traditional Uighur Medicine used for hepatitis, cholecystitis, gastralgia,
oedema, gout and arthralgia. Because of its purported effect in gout, its effects were tested in hyperuricemic mice
models induced by yeast extract paste or potassium oxonate, as well as its capacity to scavenge free radicals
in vitro.
Methods: Hyperuricemia was induced in mice by yeast extract paste or potassium oxonate. KD was given orally
for 14 days at 200, 400 and 800 mg/kg/day, with Allopurinol 10 mg/kg/day as positive control. Serum uric acid (UA),
and liver xanthine oxidase activity (XO) were measured. Scavenging activity of KD on 1, 1-diphenyl-2-picrylhydrazyl
radicals (DPP•), nitric oxide (•NO), superoxide (O2•-), efficiency against lipid peroxidation, and XO inhibition were
determined in vitro.
Results: KD inhibited liver XO activity and reduced serum uric acid in hyperuricemic mice. KD also showed
noticeable antioxidant activity, scavenging free radicals (DPP•, •NO and O2•-). It was effective against lipid
peroxidation and inhibited XO in vitro.
Conclusions: This study supports the traditional use of Karapxa decoction to treat hyperuricemia and gout.
Keywords: Karapxa decoction, Serum uric acid levels, Xanthine oxidase activities, Antioxidant, Potassium oxonate,
Traditional Uyghur medicineBackground
Hyperuricemia and gout are metabolic disorders associ-
ated with abnormal amounts of uric acid in the body
and uric acid crystals deposition or mobilisation in joints
[1]. Hyperuricemia is considered a risk factor for gout,
cardiovascular and many other diseases [2]. Uric acid,
which is poorly soluble and deposits in articular and
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unless otherwise stated.especially of xanthine by xanthine oxidase (XO). XO in-
hibitors such as allopurinol are available to block the
final step in uric acid synthesis, reducing the production
of uric acid [4]. Control of XO is a key factor in the pre-
vention and treatment of uric acid-related diseases [5,6].
Gout is mostly manifest as painful swelling of digital joints,
and can be quite incapacitating. Being both highly painful
and visible, it is a prime target of traditional therapy. How-
ever gout is but the most visible aspect of uric acid excess:
hyperuricemia and uric acid tissue deposition are associ-
ated with chronic inflammation, and increased risk of car-
diovascular diseases, diabetes mellitus, decreased cognition
in the elderly, among others. Decreasing uric acid produc-
tion may therefore have further benefits than just relieving
the painful symptoms of gout [7].his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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mula, Karapxa decoction (KD), composed of seven herbal
ingredients (Table 1), including seed, leaves or roots of cel-
ery, chicory, fennel and dodders, has long been used for
gout and arthralgia in addition to other symptoms such as
Hepatic coldness,adiposis hepatica, jaundice, hepatitis,
cholecystitis, gastralgia [8]. KD is recorded in the State
Pharmacopoeia of People’s Republic of China in the
Uighur Medicine volume. The seeds and roots of Cichor-
ium glandulosum Boiss. et Huet (Chicory) serve as an im-
portant ingredient in KD. Previous studies have shown
that extracts of Cichorium glandulosum Boiss. et Huet de-
crease serum uric acid and triglyceride concentrations in
animal models [8-10], and may also decrease hyperurice-
mia in hypertriglyceridemia models [11]. Chicory is also
commonly cited on websites for “natural” treatment of
gout. Other components of KD also have effects, such as
the hepatoprotective effect of Cuscuta chinensis against
liver toxicity of acetaminophen and other drugs [8,12,13].
It is not clear however whether KD can actually reduce
serum uric acid levels in hyperuricemia models and inhibit
XO activities. The aim of the present study was to evalu-
ate the effects of KD in vivo on reduction of serum uric
acid level and XO activity in hyperuricemic mice and to




Xanthine and XO were purchased from Sigma (St. Louis,
MO, USA). Potassium oxonate was purchased from Aldrich
Inc. 2, 2-diphenyl-1-picrylhydrazyl (DPP•), sodium nitro-
prusside, N-(1-Naphthyl) ethylenediamine dihydrochlor-
ide, phenazine methosulfate (PMS), nitroblue tetrazolium
(NBT), nicotinamide adenine dinucleotide (NADH),
Ascorbic acid (AA) and thiobarbituric acid (TBA) were
supplied by Sigma Co. (St Louis, USA). Assay kits for
serum Uric Acid (UA) were obtained from Biosino
Biotechnology Company Ltd. Assay kits for liver Xanthine
oxidase (XO) were obtained from Nanjing Jiancheng
Bioengineering Institute. All other chemicals were of
analytical grade.Table 1 Medicinal plants contained in Karapxa decoction
Botanical name Common name Uighur n
Apium graveolen L. Celery Karapxa
Apium graveolen L. Celery Karapxa
Cuscuta chinensis Lam. Dodders Sirik yog
Cichorium glandulosum Boiss. et Huet. Chicory Kasin uru
Foeniculum vulgare Mill Fennel Badranji
Cichorium glandulosum Boiss. et Huet. Chicory Kasin yiltPlant material
KD is composed of air-dried powdered raw materials
(Table 1) that were purchased from Xinjiang Autonomous
Region Traditional Uighur Medicine Hospital (Urumqi,
China) and authenticated by associate chief pharmacist
Anwar Talip. The voucher specimens (NU-110108, NU-
100908, NU-110123, NU-110113, NU-110128, NU-100111)
have been deposited in the Xinjiang Autonomous Region
Traditional Uighur Medicine Hospital (Urumqi, China).
Preparation of the aqueous extract of KD
According to the recipe of KD recommended by the
State Pharmacopoeia of People’s Republic of China, all
herbs were cut into pieces, then 1 kg herbs were mari-
nated in 10 L of warm distilled water for 12 hours. The
aqueous extract was then prepared by boiling for 30 min.
The extract was filtered and concentrated under reduced
pressure and temperature (60°C) on a rotary evaporator,
dried in vacuum conditions and stored in the refrigerator.
The yield of the extract was found to be 21.84%. The pow-
der was suspended in 0.5% sodium carboxymethylcellu-
lose (CMC-Na) solution before use.
Animals
Kunming mice weighing 18 ± 22 g were obtained from
the Experimental Animal Centre of Xinjiang Medical
University. The mice were housed in plastic cages at room
temperature of 22 ± 1°C under a 12 h light–dark cycle,
and provided with rodent chow and water ad libitum.
All procedures were in strict accordance with the
guidelines set of the Good Laboratory Practice centre at
Xinjiang Autonomous Region Traditional Uighur Medicine
Institute.
All experimental procedures used in the present study
were approved by the Ethics Committee of the Xinjiang
Medical University which has adopted the guidelines
established by the Xinjiang Uighur Autonomous Region
on Animal Care and Experimentation.
Animal model of hyperuricemia in mice
Two different in vivo hyperuricemia models were established
using yeast-induced and potassium oxonate stimulated mice,ame Family Part used Quantities
uruki Umbelliferae Seed 30 g
yiltizi Umbelliferae Root 30 g
ay uruki Convolvulaceae Seed 20 g
ki Compositae Seed 15 g
buya yiltizi posti Umbelliferae Root 30 g
izi Compositae Root 15 g
Amat et al. BMC Complementary and Alternative Medicine  (2015) 15:131 Page 3 of 8with some modifications [14,15]. Yeast contains large
amounts of purine and is used to induce hyperuricemia
in mice. For yeast-induced hyperuricemic animal model
experiments 60 mice were equally divided into 6 groups
as shown in Table 2. The normal control group was given
0.5% CMC-Na orally for 14 days. All other groups of mice
were given yeast extract paste (30 g/kg) in 0.5% CMC-Na,
orally once per day for 14 days. Group 2 was the hyperuri-
cemic animal model control. Groups 3, 4 and 5 were
treated with KD (200 mg/kg, 400 mg/kg and 800 mg/kg)
by gavage for 14 days. Group 6 were treated with allopur-
inol 10 mg/kg orally for 14 days.
The uricase inhibitor potassium oxonate was used to
induce hyperuricemia in mice [16]. Sixty mice were equally
divided into 6 groups: the normal control was given orally
only 0.5% CMC-Na for 14 days. All other mice were
injected intraperitoneally with potassium oxonate 250 mg/
kg 1 h before drug administration. Group 2 served as
hyperuricemic animal model control. Groups 3, 4 and 5
were treated with KD (200 mg/kg, 400 mg/kg and
800 mg/kg) for 14 days. Group 6 was treated with allopur-
inol 10 mg/kg orally for 14 days.
Sample collection and measurement of serum UA, liver
XO activities
Whole blood samples were collected from mice 1 h after
final administration by retro-orbital sinus puncture. The
blood was allowed to clot for approximately 1 h at room
temperature and then centrifuged at 3500 × g for 5 min
to obtain the serum. The serum was stored at −80°C until
assayed. Mouse liver was excised, frozen immediately andTable 2 Effect of Karapxa decoction (KD) or Allopurinol (AP) o
activity in yeast extract paste (YEP) and potassium oxonate (
Group Dose UA UA in
(mg/kg) (μmol/L) (%)
Normal – 6.12 ± 2.12 –
Model (YEP) – 135.5 ± 29.2Δ –
YEP + KD 200 96.7 ± 27.8** 28.6
YEP + KD 400 81.8 ± 22.9** 39.6
YEP + KD 800 65.5 ± 15.9** 51.6
YEP + AP 10 15.0 ± 3.0** 88.9
Normal – 9.53 ± 1.42 –
Model (PO) – 243.1 ± 17.2Δ –
PO + KD 200 196.3 ± 22.8** 19.2
PO + KD 400 162.5 ± 21.0** 33.2
PO + KD 800 135.5 ± 15.6** 44.3
PO + AP 10 25.0 ± 19.0** 89.7
KD: Karapxa decoction; YEP, yeast extract paste model; AP, allopurinol, PO: potassiu
ΔP <0.05 compared to normal control group.
*P < 0.05 compared to model control group.
**P < 0.01 compared to model control group.stored at −80°C until used. Tissue sample was homoge-
nized in 5 vol. of 50 mM ice-cold phosphate buffer
(pH 7.5). The homogenate was then centrifuged for
10 min at 1500 × g at 4°C. The lipid layer was carefully re-
moved and the resulting fraction centrifuged further at
10,000 × g for 30 min and the supernatant was used for as-
says. Serum UA and liver XO was determined using a
commercial kit (Nanjing Jiancheng Biochemical Reagent
Co) according to the manufacturer’s instructions. Liver
XO activities were expressed as nmol/min per mg protein.
Protein concentration was determined using a commercial
kit (Nanjing Jiancheng Biochemical Reagent Co) according
to the manufacturer’s instructions. The supernatant ob-
tained after the last centrifugation was also used for the
assays of XO activities.
Assay of xanthine oxidase activity
The XO activity was assayed spectrophotometrically under
aerobic conditions as reported with minor modifications
[17]. The assay mixture consisted of 1 ml of test solution,
2.9 ml of phosphate buffer (pH 7.5), and 0.1 ml of enzyme
solution (0.01 units/ml in phosphate buffer, pH 7.5), which
was prepared immediately before use. After preincubation
at 25°C for 15 min, the reaction was initiated by the
addition of 2 ml of substrate solution (50 mM xanthine in
the same buffer). The assay mixture was incubated at 25°C
for 30 min. The reaction was then stopped by adding of
1 ml of 1 N hydrochloric acid and absorption was mea-
sured at 290 nm using a UV spectrophotometer. A blank
was also prepared in the same way, but the enzyme solu-
tion was added to the assay mixture after adding 1 Nn serum uric acid (UA) and liver xanthine oxidase (XO)
PO) models of hyperuricemic mice in vivo
hibition Liver XO Liver XO inhibition
(U/per mg protein) (%)
1.84 ± 0.15 –
3.59 ± 0.28Δ –
3.05 ± 0.21* 15.0
2.65 ± 0.13* 26.2
2.15 ± 0.22** 40.1
1.28 ± 0.25** 64.3
1.62 ± 0.23 –
3.86 ± 0.31Δ –
3.15 ± 0.31 18.4
2.81 ± 0.13* 27.2
2.65 ± 0.22* 31.4
1.48 ± 0.15** 61.7
m oxonate model. Data represent mean ± S.E.M. of 10 animals.
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unit of XO is defined as the amount of enzyme required
to produce 1 μmol of uric acid per min at 25°C. Inhibition
of the XO activity was measured spectrophotometric-
ally at 290 nm. The percentage of inhibition of XO activ-
ity (I%) was calculated as % I = (A-B)-(C-D)/(A-B) × 100
where A is the XO activity without test extract (total uric
acid); B, the blank of A without XO; C, the enzyme activ-
ity with test extract (residual uric acid); and D, the blank
of C without the enzyme.
Antioxidant activity
Assay for DPP•-free radical scavenging activity
DPP• is a stable free radical that accepts an electron or
hydrogen radical to become a stable diamagnetic mol-
ecule. The model of scavenging the stable DPP• radical
is widely used for relatively rapid evaluation of antioxi-
dant activities. The free radical-scavenging activity of the
extract was measured in terms of hydrogen donating or
radical-scavenging ability using the stable DPP• radical.
DPP•'s purple colour shows a characteristic absorption
at 517 nm. As antioxidants scavenge the free radical by
hydrogen donation, the colour of the DPP• assay solu-
tion becomes light yellow resulting in a decrease in ab-
sorbance at 517 nm. Assay was performed in a 96-well
microplate using the previously described modified
method. Different concentrations of test sample and as-
corbic acid were prepared in ethanol and 100 μl of the
sample solution pipetted into each well and followed by
100 μl of 0.1 mM ethanolic DPP• solution. The reaction
mixture was shaken vigorously and incubated at 37°C
for 30 min. Absorbance was measured at 517 nm using
a microplate reader. The percentage inhibition (%) of the
DPP• radical by the samples was calculated using the
following equation: % inhibition = (AC – AS) /AC) × 100,
where AC is the absorbance of the control and AS is the
absorbance of the sample. The concentration required to
scavenge 50% DPP• free radicals was calculated. All deter-
minations were performed in triplicate.
Nitric oxide (•NO) radical scavenging assay
In the applied method, at physiological pH spontaneously
generated nitric-oxide interacts with oxygen to produce
nitrite ions that can be estimated using a Griess reagent.
The scavenging activity of KD towards nitric-oxide was
evaluated according to a previously described proced-
ure [18]. The reaction mixture (3 ml) containing sodium
nitroprusside (10 mM, 2 ml), 0.5 ml phosphate buffer
saline (pH 7.4, 0.01 M) and extract or standard solu-
tion (0.5 ml) was incubated at 25°C for 150 min. There-
after, 0.5 ml of the reaction mixture containing nitrite was
pipetted and mixed with 1 ml of sulfanilic acid reagent
(0.33% sulfanilic acid in 20% glacial acetic acid) and
allowed to stand for 5 min for completing diazotization.Then, 1 ml of naphthylethylenediamine dihydrochloride
(0.1%) was added, mixed and allowed to stand for 30 min.
The absorbance of pink coloured chromophore was mea-
sured at 540 nm against the corresponding blank solu-
tions. The IC50 value is the concentration of sample
required to inhibit 50% of nitric oxide free radical. All tests
were carried out in triplicates.Assay for Superoxide anion (O2·) scavenging
In the PMS–NADH–NBT system, superoxide anions are
derived from dissolved oxygen by the PMS–NADH
coupling reaction, which then reduced NBT to a blue
coloured formazan. Absorbance is measured at 560 nm.
Decrease in absorbance is directly proportional to the
antiradical potential of the product tested. Measurement
of the superoxide anion scavenging activity of KD was
based on the modified method previously reported [19].
Superoxide radicals were generated in phenazine methosul-
phate (PMS)-nicotinamide adenine dinucleotide (NADH)
systems by NADH oxidation and assayed by nitroblue
tetrazolium (NBT) reduction. In this experiment, the super-
oxide radicals were generated in 3 mL of Tris–HCl buffer
(16 mM, pH 8.0) containing 0.5 mL of NBT (300 μM) solu-
tion, 0.5 mL NADH (936 μM) solution, and 0.5 mL of KD
solution at different doses. The reaction was started by add-
ing 0.5 mL of PMS solution (120 μM) to the mixtures. The
reaction mixture was incubated at 25°C for 5 min, and the
absorbance at 560 nm measured against blank samples. All
tests were performed in triplicate and results averaged. The
percentage of inhibition was determined by comparing the
results of control and test samples.Lipid peroxidation assay
To test the in vitro inhibition of lipid peroxidation by the
extracts, lipid peroxidation induced by Fe2+/ascorbate sys-
tem in mouse liver homogenate was used and thiobarbitu-
ric acid-reactive substances (TBARS) were measured with
some modifications [20]. The reaction mixture contained
mouse liver homogenate 0.1 ml (25%, w/v) in Tris–HCl
buffer (20 mM, pH 7.0), KCl (150 mM), FeSO4 · 6H2O
(0.8 mM), ascorbic acid (0.3 mM) and various concentra-
tions of the extract in a final volume of 0.5 ml and
was incubated for 1 h at 37°C. The incubated reaction
mixture (0.4 ml) was treated with sodium dodecyl sulphate
(0.2 ml, 8%) and thiobarbituric acid (1.5 ml, 20%). The total
volume was then made up to 4 ml by adding distilled water
and kept in a water bath maintained at 100°C for 1 h. After
cooling, 1 ml of distilled water and 5 ml of n-butanol
were added and shaken vigorously to separate the buta-
nol fraction and measure TBARS formed at 535 nm. The
percentage of inhibition of lipid peroxide formation was
determined by comparing the absorbance of the treated
extract and non-treated samples.
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Values are presented as mean ± S.E.M. Analysis of vari-
ance (ANOVA) was used to test for differences among
treated and controlled groups. Inhibitory concentration
50% (IC50) of each sample was calculated by linear regres-
sion analysis using SPSS 11.0 software programme.
Results
Effect on uric acid
The effects of KD on yeast extract paste (YEP) and uri-
case inhibitor potassium oxonate (PO) induced hyperuri-
cemia in mice are shown Table 2. YEP and PO caused
hyperuricemia in mice, with serum uric acid level in-
creased to 135.5 ± 29.2 μmol/L and 243.1 ± 37.2 μmol/L,
after 10 days oral YEP or 2 h after intraperitoneal PO,
respectively. Fourteen days treatment with KD at 200,
400, 800 mg/kg effectively opposed the increase of
serum UA concentrations in both models. Allopurinol
significantly lowered serum uric acid concentrations in
experimental animals, to values not different from nor-
mal controls.
Liver XO inhibitory activity
The XO activities in normal groups were 1.84 ± 0.35 and
1.62 ± 0.23 U/per mg protein respectively. The liver XO
activities were increased to 3.56 ± 0.28 and 3.86 ± 0.31
U/per mg protein in the model control mice (p < 0.05).
KD inhibited YEP-induced XO activity by 15.0%, 26.2%,
40.1% in 200, 400 and 800 mg XD-treated mice, respect-
ively and PO-induced XO activity by 18.9%, 27.2%, 31.4%
























Figure 1 Concentration-response curves for in vitro Xanthine Oxidase in
increasing concentrations.0.05 except 200 mg, NS). Allopurinol inhibited mouse
model XO by 64.3% and 61.66% at the dose of 10 mg/kg
(both p < 0.05), obviously more than KD (Table 2).
In vitro effects
Inhibition of xanthine oxidase
At a concentration of 250 μg/ml KD, uric acid formation
was completely suppressed; the IC50 value for KD inhib-
ition was 25.8 μg/ml. Allopurinol had an IC50 value of
6.28 μg/ml (Figure 1).
DPP• radical scavenging
The results concerning DPP• free radical scavenging ef-
fect of KD are indicated in Table 3. KD was a potent
DPP• free radical scavenger. This activity was 31.1%,
45.2%, and 65.2%, respectively, for 25, 50, and 100 μg/
ml of KD (all p < 0.05). The IC50 value was calculated
to be 55.6 μg/ml.
Nitric oxide (•NO) radical scavenging
The efficiency of KD to scavenge •NO free radical is pre-
sented in Table 3. KD was found to possess strong NO
scavenging ability, showing concentration-dependent ac-
tivity (p < 0.05). The IC50 value was 31.4 μg/ml.
Superoxide anion radical scavenging
As shown in Table 3, KD exhibited significant and con-
centration dependent O2•- scavenging activity (5.8–83.5%
inhibition, p < 0.05 for concentrations above 6.25 μg/ml)
at 6.25-400 μg/ml, The IC50 value was calculated to be
89.3 μg/ml for a scavenging effect at 49.7%.25µg/ml 50µg/ml 100µg/ml 
KD
AP
hibition (in %) by Xarapxa decoction (XD) or allopurinol (AP) at
Table 3 Effect of increasing concentrations of Karapxa decoction (KD) on radical scavenging with DPP•, Nitric oxide
(•NO), Superoxide, and lipid peroxidation models, compared to ascorbic acid or butylated toluene controls
Product Concentration (μg/ml) DPP• scavenging (%) •NO scavenging (%) Superoxide scavenging (%) Lipid peroxidation inhibition (%)
KD 3.13 μg/ml 6.13 ± 1.23 13.3 ± 1.89 4.8 ± 0.4 12.0 ± 2.65
KD 6.25 μg/ml 15.7 ± 1.46 31.3 ± 2.72 8.6 ± 4.23 21.2 ± 3.33
KD 12.50 μg/ml 31.1 ± 3.21 49.1 ± 2.84 23.0 ± 3.69 29.3 ± 2.15
KD 25.0 μg/ml 45.2 ± 2.56 64.2 ± 5.52 33.4 ± 4.12 43.4 ± 4.96
KD 50.0 μg/ml 65.2 ± 3.14 71.5 ± 4.82 49.7 ± 3.88 48.5 ± 4.48
KD 100.0 μg/ml 82.2 ± 3.67 83.3 ± 2.52 69.1 ± 5.19 65.7 ± 4.18
AA 50.0 μg/ml 84.3 ± 4.68 39.2 ± 3.39
BHT 50.0 μg/ml 21.1 ± 2.43 61.1 ± 2.91
KD: Karapka decoction; AA: Ascorbic acid; BHT: Butylated hydroxytoluene.
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KD displays dose-dependent lipid peroxidation inhibition,
and this activity was 24.5%, 34.2%, 48.3%, and 63.5%, for
25 μg/ml, 50 μg/ml, 100 μg/ml, and 200 μg/ml KD (all p <
0.05). The concentration of KD needed for 50% inhibition
was found to be 111.3 μg/ml (Table 3).
Discussion
Karapka decoction had dose-dependent effects on uric
acid concentration and xanthine oxidase activity in two
different hyperuricemic mice models. In addition, KD
had free radical scavenging activities in vitro.
Gout and hyperuricemia are increasingly common dis-
orders, reportedly afflicting more than 2 million men
and women in the United States alone [21], and is pro-
gressing rapidly in China due probably to recent changes
in dietary habits [22]. Gout and hyperuricemia are meta-
bolic disorders associated with abnormal uric acid concen-
trations in the body, resulting in the deposition of urate
crystals in the joints and kidneys that lead to inflamma-
tion, as well as gouty arthritis and uric acid nephrolithia-
sis. In addition to an increased risk of hyperuricemia and
gout, excess uric acid is also related to cardiovascular dis-
orders, nephrolithiasis, diabetes [7,23-32].
Two major mechanisms have been proposed for hyperu-
cicemia in man, excess production and insufficient meta-
bolisation of uric acid. Yeast extract paste and potassium
oxonate were used to mimic both mechanisms: yeast rep-
resents excess production of UA, probably the main mech-
anism in man, and oxonate impairs metabolisation [15,23].
Yeast disturbs normal purine metabolism by increasing
xanthine oxidase (XO) activity and generating large quan-
tities of uric acid. This model is similar to human hyperuri-
cemia, which is induced by high-protein diets. Another
mouse hyperuricemia model was generated by a single in-
traperitoneal injection of potassium oxonate 250 mg/kg.
Potassium oxonate, a urate oxidase inhibitor, can raise the
serum uric acid concentration by inhibiting the decompos-
ition of uric acid by uricase, an enzyme that does not existin man. Karapxa was found approximately equally effective
in both models, but less than allopurinol.
Many bioactive products have been identified from the
herbs in the KD formula and pharmacological activity of
those herbs has been reported. Celery seeds are used in
arthritic pain relief, for treating rheumatic conditions and
gout [33,34]. Essential oil, fatty acid, flavonoids isolated
from Apium graveolen L., possesses antibacterial, antioxi-
dative, hepaprotective, anti-tumor, and anti-cardiovascular
disease abilities [35,36]. Certain indole-like compounds
and indole alkaloids isolated from A. graveolens seeds were
found to have antioxidant, cyclooxygenase and topoisom-
erase inhibitory activity [37]. The seeds of Cuscuta chinen-
sis Lam. (Convolvulaceae), is a commonly used traditional
Chinese herbal medicine used in improving and condition-
ing the liver and the kidney and also possesses anticancer
effects, immunostimulant, antioxidant, and hepatoprotec-
tive activities [13,38-41].
The active constituents of C. chinensis include flavo-
nol, flavonoids, lignans, quinic acid, and polysaccharide
[42-45], which have been suggested to be responsible for
the pharmacological activities observed from C. chinensis
[46,47]. Cichorium glandulosum Boiss. et Huet is well
known in Uighur medicine use for curing liver diseases,
etc. In the Chinese Pharmacopoeia of the People’s Repub-
lic of China, “Juju” (Herba Cichorii and Radix Cichorii) re-
fers to the aerial parts and roots of Cichorium intybus L.
and Cichorium glandulosum Boiss. et Huet. Different
parts of these plants have been analysed, mostly for the
presence of phenolics and sesquiterpene lactones. The
major phenolics include flavonoids, coumarins and caffeic
acid derivatives [48].
Many pharmacological studies on the same compounds
have been performed earlier, finding anti-diabetic [49],
antibacterial [50], hepatoprotective [12] and antioxidant
effects. These constituents may be present at different
amounts in the KD extracts and it is far from established
which constituent(s) are responsible for the effects of the
extracts. Further investigations are warranted to identify
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for the observed hypouricemic effects.
Conclusion
The objective of the present study was to test the hypouri-
cemic and antioxidant effects of the KD, which is used in
traditional Uighur medicine to treat gout and hyperurice-
mia. The results suggest that KD at the dosage of 200, 400
and 800 mg/kg has hypouricemic effects in both hyper-
uricemic mouse models. KD was also found to have in-
hibitory effects on mouse liver XO activity. Antioxidant
activity was evident, through the ability to scavenge sev-
eral free radicals (DPPH, NO and O2
. ) and the effect on
lipid peroxidation.
These results, though there is still a need for clinical
validation, support the traditional use of KD to prevent
or treat hyperuricemia and gout. It was less powerful
than allopurinol, but may have the advantages of low
cost and high acceptability in countries with limited re-
sources or with a tradition of herbal medicinal treatment
of diseases.
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